Development of analytical technology in pharmacogenetic research

被引:8
作者
Daly, AK [1 ]
机构
[1] Univ Newcastle Upon Tyne, Sch Med, Sch Clin & Lab Sci, Pharmacogenet Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
genotype; phenotype; polymerase chain reaction; pharmacogenetics; mutation detection;
D O I
10.1007/s00210-003-0794-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Methods used to determine phenotype and genotype for pharmacogenetic polymorphisms are discussed. Phenotyping is mainly applicable to polymorphisms affecting drug disposition rather than drug response and can involve either direct measurement of enzyme activity or administration of a probe drug followed by measurement of drug and/or metabolite levels. Genotyping is now more widely used than phenotyping and can be used to determine genotype for polymorphisms affecting either drug disposition (for example those in the cytochromes P450 or N-acetyltransferases) or drug response (for example those in drug receptors). Most genotyping for known polymorphisms involves use of the polymerase chain reaction and the wide variety of methods based on this technique that are now used for routine genotyping are discussed in detail. In addition, a range of methods that can be used to detect novel polymorphisms, thereby further increasing understanding of interindividual variability in drug disposition and response, is described.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 65 条
[1]   Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing [J].
Alderborn, A ;
Kristofferson, A ;
Hammerling, U .
GENOME RESEARCH, 2000, 10 (08) :1249-1258
[2]   TRIMETHYLAMINURIA - THE DETECTION OF CARRIERS USING A TRIMETHYLAMINE LOAD TEST [J].
ALWAIZ, M ;
AYESH, R ;
MITCHELL, SC ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF INHERITED METABOLIC DISEASE, 1989, 12 (01) :80-85
[3]  
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[4]   GENOTYPE-PHENOTYPE DISCORDANCE FOR HUMAN ARYLAMINE N-ACETYLTRANSFERASE (NAT2) REVEALS A NEW SLOW-ACETYLATOR ALLELE COMMON IN AFRICAN-AMERICANS [J].
BELL, DA ;
TAYLOR, JA ;
BUTLER, MA ;
STEPHENS, EA ;
WIEST, J ;
BRUBAKER, LH ;
KADLUBAR, FF ;
LUCIER, GW .
CARCINOGENESIS, 1993, 14 (08) :1689-1692
[5]   A URINARY METABOLITE RATIO THAT REFLECTS SYSTEMIC CAFFEINE CLEARANCE [J].
CAMPBELL, ME ;
SPIELBERG, SP ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (02) :157-165
[6]   Characterization of single-nucleotide polymorphisms in coding regions of human genes [J].
Cargill, M ;
Altshuler, D ;
Ireland, J ;
Sklar, P ;
Ardlie, K ;
Patil, N ;
Lane, CR ;
Lim, EP ;
Kalyanaraman, N ;
Nemesh, J ;
Ziaugra, L ;
Friedland, L ;
Rolfe, A ;
Warrington, J ;
Lipshutz, R ;
Daley, GQ ;
Lander, ES .
NATURE GENETICS, 1999, 22 (03) :231-238
[7]   Pitfalls in N-acetyltransferase 2 genotyping [J].
Cascorbi, I ;
Roots, I .
PHARMACOGENETICS, 1999, 9 (01) :123-127
[8]   Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [J].
Chang, M ;
Dahl, ML ;
Tybring, G ;
Gotharson, E ;
Bertilsson, L .
PHARMACOGENETICS, 1995, 5 (06) :358-363
[9]   The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry [J].
Chen, SQ ;
Chou, WH ;
Blouin, RA ;
Mao, ZP ;
Humphries, LL ;
Meek, C ;
Neill, JR ;
Martin, WL ;
Hays, LR ;
Wedlund, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (05) :522-534
[10]   COMPARISON OF A NOVEL THIN-LAYER CHROMATOGRAPHIC-FLUORESCENCE DETECTION METHOD WITH A SPECTROFLUOROMETRIC METHOD FOR THE DETERMINATION OF 7-HYDROXYCOUMARIN IN HUMAN URINE [J].
CHOLERTON, S ;
IDLE, ME ;
VAS, A ;
GONZALEZ, FJ ;
IDLE, JR .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 575 (02) :325-330